Kinetics of H2AX phosphorylation after exposure to cisplatin
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Cisplatin is a widely used cancer chemotherapeutic drug that causes DNA crosslinking and stimulates H2AX phosphorylation. Our goal was to assess the potential of γH2AX to help predict tumor response to cisplatin treatment. Methods: The kinetics of cisplatin‐induced DNA interstrand crosslinks was measured using the alkaline comet assay and compared with γH2AX formation and clonogenic cell survival in several DNA repair proficient or deficient human and rodent cell lines. Results: The comet assay was effective in ranking cell lines according to their relative sensitivity to cisplatin based on reduced crosslink formation measured 6 h after drug exposure or by the failure of irs3 and UV41 cell lines to subsequently remove crosslinks. In comparison, the initial rate of phosphorylation of H2AX measured over the first 6 h after cisplatin treatment was unrelated to drug sensitivity or crosslinking proficiency. However, for proliferating cell cultures, the fraction of cells that retained γH2AX foci 24 h after cisplatin treatment was correlated with the fraction of cells that lost clonogenic potential (slope = 1.1, r2 = 0.85). Conclusions: H2AX phosphorylation occurs in response to replication fork damage caused by cisplatin induced DNA lesions, probably interstrand crosslinks. Although early kinetics of γH2AX formation was uninformative, retention of γH2AX foci 24 h after treatment was shown to be a useful indicator of cell response to killing by cisplatin. However, for γH2AX to serve as an indicator of cell viability after cisplatin treatment, cells must have the opportunity to transit S phase during the recovery period. © 2008 Clinical Cytometry Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks
Celeste, A., Fernandez-Capetillo, O., Kruhlak, M. J., Pilch, D. R., Staudt, D. W., Lee, A., Bonner, R. F., Bonner, W. M., & Nussenzweig, A. (2003) · Nature Cell Biology · doi:10.1038/ncb1004 · Cited by 989
Histone H2AX Phosphorylation as a Predictor of Radiosensitivity and Target for Radiotherapy
Taneja, N., Davis, M., Choy, J. S., Beckett, M. A., Singh, R., Kron, S. J., & Weichselbaum, R. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310030200 · Cited by 281
Limoli, C. L., Giedzinski, E., Bonner, W. M., & Cleaver, J. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231611798 · Cited by 210
RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult
Bosco, E. E. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkg919 · Cited by 97
Cited by
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
The Human Gut Bacterial Genotoxin Colibactin Alkylates DNA
Wilson, M. R., Jiang, Y., Villalta, P. W., Stornetta, A., Boudreau, P. D., Carrá, A., Brennan, C. A., Chun, E., Ngo, L., Samson, L. D., et al. (2019) · Science · doi:10.1126/science.aar7785 · Cited by 635
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Zheng, Y.-R., Suntharalingam, K., Johnstone, T. C., Yoo, H., Lin, W., Brooks, J. G., & Lippard, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5038269 · Cited by 440
Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., & Patrick, S. M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.010 · Cited by 182
“γ-H2AX foci also form upon exposure to cisplatin, although detection of DSBs in certain instances has been shown to be limited [31].”
Rocha, C. R. R., Garcia, C. C. M., Vieira, D. B., Quinet, A., de Andrade-Lima, L. C., Munford, V, Belizário, J. E., & Menck, C. F. M. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.465 · Cited by 164
“been widely used as a DSBmarker.(12,13) Our results pointed to a reduced percentage of γH2AX-positive cells in the resistant cells (Figure 2b), indicating that fewer DSBswere generated in U138MG cells after being treated with cisplatin.”
MethodNucleotide excision repair activity on DNA damage induced by photoactivated methylene blue
Berra, C. M., de Oliveira, C. S., Garcia, C. C. M., Rocha, C. R. R., Lerner, L. K., Lima, L. C. D. A., Baptista, M. D. S., & Menck, C. F. M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.026 · Cited by 40
Glutamine deprivation counteracts hypoxia-induced chemoresistance
Wappler, J., Arts, M., Röth, A., Heeren, R. M. A., Peter Neumann, U., Olde Damink, S. W., Soons, Z., & Cramer, T. (2020) · Neoplasia · doi:10.1016/j.neo.2019.10.004 · Cited by 34
Metadata
- Authors
- Olive, P. L., & Banáth, J. P.
- Venue
- Cytometry Part B: Clinical Cytometry
- Publisher
- Wiley
- Published
- 2008-08-25
- Volume
- 76B
- Issue
- 2
- Pages
- 79-90
- ISSN
- 1552-4949 (ISSN-L)
- 1552-4957
- OpenAlex
- W2060371289
- Cited by
- 158
- References
- 5
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.